CXCL12 and cancer: In this work, we applied several computational methods, including extensive all-atom molecular dynamics simulations, to characterize the binding mechanism of motixafortide—a promising compound currently involved in clinical trials for different types of cancer that regulates the CXCL12–CXCR4 signaling axis [16].